NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE226866 Query DataSets for GSE226866
Status Public on Mar 17, 2023
Title RNA sequencing/Gene expression studies of CSK inhibitor (CSKi) in diffuse large B-cell lymphoma (DLBCL) [JC2]
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary We determined that CSKi treatment affects oncogenic signaling in DLBCL. We sought to measure gene expression change in DLBCL cells by RNA-sequencing following CSKi treatment.
 
Overall design TMD8 and DOHH2 cells were treated in duplicates with DMSO or CSKi (500nm) for 1h, 3h, 6h and 24h.
 
Contributor(s) Choi J, Staudt LM
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Mar 07, 2023
Last update date Mar 17, 2023
Contact name David Huang
Organization name National Cancer Institute
Street address 9000 Rockville Pike
City Bethesda
State/province Maryland
ZIP/Postal code 20892-0001
Country USA
 
Platforms (1)
GPL30173 NextSeq 2000 (Homo sapiens)
Samples (32)
GSM7086074 DOHH2_DMSO_1h bio replicate1
GSM7086075 DOHH2_DMSO_1h bio replicate2
GSM7086076 DOHH2_CSKi_1h bio replicate1
This SubSeries is part of SuperSeries:
GSE225858 Targeting oncogenic BCR signaling therapeutically by glucocorticoids and CSK inhibition
Relations
BioProject PRJNA941913

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE226866_DLBCL_CSKi_RNAseq_Normalized_log2.txt.gz 1.4 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap